Spots Global Cancer Trial Database for Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT

Official Title: Reduced Intensity Myeloablative Total Body Irradiation and Thymoglobulin Followed by Allogeneic Peripheral Blood Stem Cell Transplantation

Study ID: NCT00709592

Conditions

Non-Hodgkin's Lymphoma

Leukemia

Multiple Myeloma

Acute Myeloid Leukemia

Hodgkin Lymphoma

Chronic Lymphocytic Leukemia

Chronic Myelogenous Leukemia

Myelodysplastic Syndrome

Interventions

Thymoglobulin

Total-Body Irradiation

Allogeneic PBSCT or BMT

Tacrolimus

Mycophenolate Mofetil

Study Description

Brief Summary: One of two different doses of thymoglobulin will allow bone marrow engraftment with minimal Graft-versus-Host Disease and allow adequate immune response to allow the transplanted stem cells to replace the tumor cells.

Detailed Description: This randomized phase II trial studies how well giving low dose total-body irradiation (TBI) with anti-thymocyte globulin followed by donor peripheral blood stem cell transplant (PBSCT) works in treating patients with hematologic malignancies. Giving reduced intensity total-body irradiation and anti-thymocyte globulin before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving total-body irradiation together with antithymocyte globulin before transplant may stop this from happening.